BPD Clinical Trial
— DBT+ContextOfficial title:
Clinical Trial of Skills Training for Long Lasting Symptoms in Borderline Personality Disorder
Although borderline personality disorder (BPD) tend to the clinical remission in long-term follow-up studies, a significant subgroup of patients continues to present long lasting symptoms such as low mood, emptiness and persistent impairment in psychosocial adjustment. The prevalence of this subsample of individuals is considerably increasing last years. New interventions addressed to these individuals are need, the aim of this study is to evaluate the efficacy of a novel intervention combining dialectical behavioral therapy skills training with self-compassion and contextual-based skills for patients with long-lasting BPD.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | October 1, 2023 |
Est. primary completion date | October 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Adults between 18 and 65 years of age - Primary diagnosis of BPD according to Diagnostic Statistical Manual IV criteria and by the structured interviews: Diagnosis Structured clinical interview for axis II personality disorders (SCID II; First et al. 1997) and Diagnostic Interview for Borderlines Revised (DIB-R) - Previous participation in DBT-ST intervention - Signed informed consent. Exclusion Criteria: - Presence of life-threatening behaviors in the last 12 months - PTSD or related symptoms - Diagnosis of drug-induced psychosis, organic brain syndrome, bipolar or psychotic disorder - Intellectual disability - Participation in any other psychotherapy treatment during the study. |
Country | Name | City | State |
---|---|---|---|
Spain | Juan Carlos Pascual Mateos | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pemberton Happiness Index (PHI) | Happiness index (minimum 0- maximum 110) Higher scores better | 1 month | |
Secondary | Borderline Symptoms List-23 (BSL-23) | Symptoms of Borderline (minimum 0- maximum 92). Higher scores worse | 1 week | |
Secondary | Remission from Depression Questionnaire (RDQ) | Depression (minimum 0- maximum 84). Higher scores worse | 1 week | |
Secondary | Self Compassion Scale Short Form (SCS-SF) | Compassion scale (12 items, minimum 12- maximum 60). Higher scores worse | 1 month | |
Secondary | Forms of Self-Criticism/Self-Attacking and Self-Reassuring Scale (FSCRS) | Self-criticism forms (14 items, minimum 0- maximum 56). Higher scores worse | 1 month | |
Secondary | Satisfaction with life scale (SWLS) | Well being (5 items, minimum 5 - maximum 25). Higher scores better | 1 month | |
Secondary | Quality of life scale (WHO-QOL_BREF) | Quality of life OMS (26 items, minimum 26- maximum 130). Higher scores better | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Not yet recruiting |
NCT05071638 -
Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neonates
|
Phase 3 | |
Recruiting |
NCT04440670 -
Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates
|
Phase 3 |